Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999416 | 0.90 | SRD5A2 (0.72) | SRD5A2NR3C1CA2CAMK2AFFAR1 | |
| SCHEMBL21243832 | 0.90 | SRD5A2 (0.72) | SRD5A2NR3C1CA2CAMK2AFFAR1 | |
| SCHEMBL104746 | 0.88 | CA2 (0.62) | CA2CAMK2AFFAR1CTBP2AKR1B1 | |
| Hydrochloric Acid SCHEMBL2170212 | 0.86 | CA2 (0.60) | CA2CAMK2AFFAR1CTBP2AKR1B1 | |
| Methane SCHEMBL1421956 | 0.86 | CA2 (0.60) | CA2CAMK2AFFAR1CTBP2AKR1B1 | |
| Fluoride SCHEMBL11185179 | 0.86 | CA2 (0.60) | CA2CAMK2AFFAR1CTBP2AKR1B1 | |
| SCHEMBL11596764 | 0.85 | NR4A2 (0.54) | LTA4HNR4A2FFAR1LMNA | |
| SCHEMBL1145770 | 0.84 | SRD5A2 (0.83) | SRD5A2LTA4HNR3C1FFAR1AKR1B1 | |
| SCHEMBL3500162 | 0.84 | NR4A2 (0.71) | CA2NR4A2FFAR1 | |
| Hydrazine SCHEMBL18601422 | 0.84 | CA2 (0.58) | CA2CAMK2AFFAR1CTBP2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-0946495-B1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6353128-B1 | FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK. | ELI LILLY AND COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-0946495-A4 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0946495-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024756-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | SRD5A2 1140/4885LTA4H 1788/4885EPHX2 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.